Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

PharmaPoint: HER2-Positive Breast Cancer - 5EU Drug Forecast and Market Analysis to 2023

Published: Sep-2014 | Format: PDF | GlobalData | Number of pages: 196 | Code: MRS - 2002

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

 

As in the other seven countries covered in this report, Herceptin is the market leader in France, since it was the first HER2-targeting agent to market. Newly-approved drugs tend to gain market access faster in Germany than in the other four EU countries, and this is reflected in the use of Perjeta and Kadcyla in the German HER2-positive breast cancer market. In 2013, Herceptin was the market leader, accounting for 94% of sales in the Italian HER2-positive market. There will be an increase in the breast cancer market size in Spain during the forecast period due to the increased use of HER2-targeted therapies in the neoadjuvant setting, in particular, Perjeta, which is already approved for use in this setting in the US.

 

Scope

 

  • An overview of HER2-Positive Breast Cancer, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized the 5EU HER2-Positive Breast Cancer market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for HER2-Positive Breast Cancer.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the HER2-Positive Breast Cancer sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

 

Reasons to Buy

 

  • Understand the trends shaping and driving the 5EU HER2-Positive Breast Cancer market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in the 5EU HER2-Positive Breast Cancer market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in the 5EU HER2-Positive Breast Cancer market landscape Identify, understand and capitalize.

Table of Contents

 

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

 

2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports

 

3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Basic Breast Anatomy
3.3 Breast Cancer Staging
3.4 Prognosis
3.5 Quality of Life
3.6 Symptoms

 

4 Disease Management
4.1 Treatment Overview
4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)
4.2 France
4.2.1 Diagnosis
4.2.2 Clinical Practice
4.3 Germany
4.3.1 Diagnosis
4.3.2 Clinical Practice
4.4 Italy
4.4.1 Diagnosis
4.4.2 Clinical Practice
4.5 Spain
4.5.1 Diagnosis
4.5.2 Clinical Practice
4.6 UK
4.6.1 Diagnosis
4.6.2 Clinical Practice

 

5 Competitive Assessment
5.1 Overview
5.2 Product Profiles - HER2-Targeted Therapies
5.2.1 Herceptin (trastuzumab)
5.2.2 Tykerb (lapatinib)
5.2.3 Perjeta (pertuzumab)
5.2.4 Kadcyla (ado-trastuzumab emtansine, T-DM1)
5.3 Product Profiles - General Targeted Therapies
5.3.1 Afinitor (everolimus)
5.3.2 Xeloda (capecitabine)
5.3.3 Avastin (bevacizumab)
5.3.4 Halaven (eribulin mesylate)
5.3.5 Abraxane (nab-paclitaxel)
5.4 Hormonal Agents
5.4.1 Tamoxifen
5.4.2 Faslodex (fulvestrant)
5.4.3 Aromatase Inhibitors

 

6 Unmet Need and Opportunity
6.1 Overview
6.2 Brain Metastases
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.2.3 Opportunity
6.3 Resistance to HER2-Targeting Therapies
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.3.3 Opportunity

 

7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Gilotrif (afatinib)
7.2.2 Neratinib
7.3 Promising Drugs in Early-Stage Development
7.3.1 Palbociclib
7.3.2 NeuVax (nelipepimut-S)
7.3.3 Patritumab
7.3.4 Ganetespib
7.3.5 ARRY-380 (ONT-380)
7.3.6 NVP-BYL719
7.4 Biosimilars

 

8 Market Outlook
8.1 Global Markets
8.1.1 Drivers and Barriers - Global Issues
8.2 France
8.2.1 Forecast
8.2.2 Key Events
8.2.3 Drivers and Barriers
8.3 Germany
8.3.1 Forecast
8.3.2 Key Events
8.3.3 Drivers and Barriers
8.4 Italy
8.4.1 Forecast
8.4.2 Key Events
8.4.3 Drivers and Barriers
8.5 Spain
8.5.1 Forecast
8.5.2 Drivers and Barriers
8.6 United Kingdom
8.6.2 Key Events
8.6.3 Drivers and Barriers

 

9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed HER2-Positive Breast Cancer Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Generic Erosion
9.4.8 Pricing of Pipeline Agents
9.5 Primary Research - KOLs Interviewed for this Report
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.1 Analyst
9.7.2 Therapy Area Director
9.7.3 Global Head of Healthcare
9.8 About GlobalData
9.9 Disclaimer

 

List of Table

 

Table 1: AJCC Stage Definitions for Breast Cancer
Table 2: Prognosis for Breast Cancer in the US
Table 3: Treatment Guidelines for HER2-Positive Breast Cancer
Table 4: Product Profile - Herceptin
Table 5: Clinical Studies for Herceptin in the Adjuvant Setting
Table 6: Herceptin SWOT Analysis, 2013
Table 7: Product Profile - Tykerb
Table 8: Tykerb SWOT Analysis, 2013
Table 9: Product Profile - Perjeta
Table 10: Perjeta SWOT Analysis, 2013
Table 11: Product Profile - Kadcyla
Table 12: Kadcyla SWOT Analysis, 2013
Table 13: Product Profile - Afinitor
Table 14: Afinitor SWOT Analysis, 2013
Table 15: Product Profile - Xeloda
Table 16: Xeloda SWOT Analysis, 2013
Table 17: Product Profile - Avastin
Table 18: Summary of Avastin Phase III Clinical Trials in Metastatic Breast Cancer
Table 19: Avastin SWOT Analysis, 2013
Table 20: Product Profile - Halaven
Table 21: Halaven SWOT Analysis, 2013
Table 22: Product Profile - Abraxane
Table 23: Abraxane SWOT Analysis, 2013
Table 24: Summary of Minor Therapeutic Classes Used to Treat HER-2 positive breast cancer, 2013
Table 25: Unmet Need and Opportunity in HER2-Positive Breast Cancer
Table 26: Product Profile - Gilotrif
Table 27: Gilotrif SWOT Analysis, 2014
Table 28: Product Profile - Neratinib
Table 29: Neratinib SWOT Analysis, 2013
Table 30: Comparison of Therapeutic Classes in Development for HER2-Positive/HER2-Negative Breast Cancer, 2014
Table 31: HER2-Positive Breast Cancer - Early-Phase Pipeline, 2014
Table 32: Product Profile - Palbociclib
Table 33: Palbociclib SWOT Analysis, 2014
Table 34: Product Profile - NeuVax
Table 35: NeuVax SWOT Analysis, 2014
Table 36: Product Profile - Patritumab
Table 37: Patritumab SWOT Analysis, 2014
Table 38: Product Profile - Ganetespib
Table 39: Ganetespib SWOT Analysis, 2014
Table 40: Product Profile - ARRY-380
Table 41: ARRY-380 SWOT Analysis, 2014
Table 42: Product Profile - NVP-BYL719
Table 43: NVP-BYL719 SWOT Analysis, 2014
Table 44: Trastuzumab Biosimilars, 2014
Table 45: Global HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 46: Sales Forecast ($m) for HER2-Positive Breast Cancer in France, 2013-2023
Table 47: Key Events Impacting Sales for HER2-Positive Breast Cancer in France, 2013-2023
Table 48: French HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 49: Sales Forecast ($m) for HER2-Positive Breast Cancer in Germany, 2013-2023
Table 50: Key Events Impacting Sales for HER2-Positive Breast Cancer in Germany, 2013-2023
Table 51: German HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 52: Sales Forecast ($m) for HER2-Positive Breast Cancer in Italy, 2013-2023
Table 53: Key Events Impacting Sales for HER2-Positive Breast Cancer in Italy, 2013-2023
Table 54: Italian HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 55: Sales Forecast ($m) for HER2-Positive Breast Cancer in Spain, 2013-2023
Table 56: Key Events Impacting Sales for HER2-Positive Breast Cancer in Spain, 2013-2023
Table 57: Spanish HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 58: Sales Forecast ($m) for HER2-Positive Breast Cancer in the UK, 2013-2023
Table 59: Key Events Impacting Sales for HER2-Positive Breast Cancer in the UK, 2013-2023
Table 60: UK HER2-Positive Breast Cancer Market - Drivers and Barriers, 2013-2023
Table 61: HER2-Positive Breast Cancer Incidence, 2013-2023
Table 62: HER2-Positive Breast Cancer Drugs, Key Launch Dates
Table 63: HER2-Positive Breast Cancer Drugs, Key Patent Expiries
Table 64: Average Body Weight and Surface Area Across the 5EU Markets
Table 65: Average Annual Cost of Therapy ($) - Herceptin, Adjuvant
Table 66: Average Annual Cost of Therapy ($) - Subcutaneous Herceptin, Adjuvant
Table 67: Average Annual Cost of Therapy ($) - Perjeta, First Line
Table 68: Average Annual Cost of Therapy ($) - Tykerb, First Line
Table 69: Average Annual Cost of Therapy ($) - Kadcyla, Second Line
Table 70: Average Annual Cost of Therapy ($) - Halaven, Fourth Line
Table 71: Average Annual Cost of Therapy ($) - Abraxane, Fourth Line
Table 72: Average Annual Cost of Therapy ($) - Neratinib, Third Line
Table 73: Physicians Surveyed by Country

 

List of Figures

 

Figure 1: Basic Breast Anatomy, Including Key Lymph Nodes
Figure 2: Primary Completion Dates of Active Phase III Clinical Trials for Tykerb
Figure 3: Active Late-Stage Clinical Trials for Perjeta
Figure 4: Active Phase III Clinical Trials for Kadcyla
Figure 5: Active Phase III Clinical Trials for Afinitor
Figure 6: Clinical Trials for Halaven
Figure 7: HER2-Positive Breast Cancer - Phase II-III Pipeline, 2013
Figure 8: Gilotrif's Clinical Development in Breast Cancer
Figure 9: Clinical and Commercial Positioning of Gilotrif
Figure 10: Neratinib's Clinical Development
Figure 11: Clinical and Commercial Positioning of neratinib.
Figure 12: Sales for HER2-Positive Breast Cancer in France by Drug Class, 2013-2023
Figure 13: Sales for HER2-Positive Breast Cancer in Germany by Drug Class, 2013-2023
Figure 14: Sales for HER2-Positive Breast Cancer in Italy by Drug Class, 2013-2023
Figure 15: Sales for HER2-Positive Breast Cancer in Spain by Drug Class, 2013-2023
Figure 16: Sales for HER2-Positive Breast Cancer in the UK by Drug Class, 2013-2023

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)10995 View Pricing